Clinical Trials Logo

Macular Edema clinical trials

View clinical trials related to Macular Edema.

Filter by:

NCT ID: NCT03384524 Withdrawn - Clinical trials for Diabetic Macular Edema

Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME

Start date: March 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is designed to provide proof of concept evidence that combination therapy can have a beneficial effect on DME and possibly prevent increases in retinal volume or progression of non-central DME into the central subfield of the macula. If a beneficial effect is apparent in this phase I/II study involving a relatively small sample size and short follow-up period, its results could be used to in plan future phase III trials. We believe this study will be the first to show that a systems pharmacology approach can successfully address diabetic macular edema, and thus revolutionize the treatment of complex retinal diseases for which there are a paucity of effective treatment options.

NCT ID: NCT03059277 Withdrawn - Clinical trials for Diabetic Macular Edema

Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the efficacy of intravitreal aflibercept injections administered in a treat and extend fashion in eyes that have persistent center involved diabetic macular edema following at least 4 intravitreal injections of 0.3 mg ranibizumab over 24 weeks.

NCT ID: NCT02902744 Withdrawn - Clinical trials for Diabetic Macular Edema

Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study

FAD
Start date: March 1, 2017
Phase: Phase 4
Study type: Interventional

Primary Objective: • To collect post-approval safety data related to intraocular pressure (IOP) after one or more injections of Iluvien as standard of care in subjects with diabetic macular edema (DME). Secondary Objectives: • To collect visual and anatomic outcome data after one or more injections of Iluvien as standard of care in subjects with diabetic macular edema (DME).

NCT ID: NCT02878681 Withdrawn - Clinical trials for Visual Impairment Due to Diabetic Macular Edema

24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.

TIDE DME
Start date: September 2016
Phase: Phase 4
Study type: Interventional

The purpose of the study is to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF levels in DME patients in a detailed time course.

NCT ID: NCT02842541 Withdrawn - Clinical trials for Diabetic Macular Edema

Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema

Start date: September 2016
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of up to 3 dose levels of EBI-031 given as an intravitreal injection in subjects with diabetic macular edema. There are two arms to the study, a single dose arm (1 dose) and a repeat dose arm (1 dose each month for 3 months). Eligible subjects will initially enroll in the single dose arm and 3 to 6 subjects will be dosed at each of the 3 dose levels. Safety will be assessed over the 28 days after the single dose prior to moving to the next higher dose level. Once all subjects in the single dose arm have been dosed with EBI-031 and the safety has been assessed eligible subjects will begin enrolling in the repeat dose arm. Subjects in the repeat dose arm will receive one dose each month for 3 months and will be assessed for safety. Escalation to the next higher dose will occur once it is determined safe to proceed to the next dose level. Six subjects will be dosed at each of the 3 dose levels.

NCT ID: NCT02598869 Withdrawn - Uveitis Clinical Trials

Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema

Start date: November 30, 2015
Phase: Phase 4
Study type: Interventional

Macular edema is the most common sight threatening complication of uveitis which can lead to permanent loss of central vision. Triamcinolone acetonide ( the study drug)injection for treatment of cystoid macular edema(CME) is well established. The purpose of this study is to compare the safety and efficacy of injecting the study drug inside the eye(intravitreal injection) and behind the eye(subtenon injection)

NCT ID: NCT02511067 Withdrawn - Clinical trials for Diabetic Macular Edema

Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study

READ-4
Start date: October 1, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety, tolerability and efficacy of Ranibizumab and Tocilizumab alone and in combination in eyes with Diabetic Macular Edema.

NCT ID: NCT02349516 Withdrawn - Clinical trials for Diabetic Retinopathy

Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)

Start date: February 2015
Phase: Phase 2
Study type: Interventional

A randomized, controlled study of the safety and efficacy of Squalamine Lactate Eye Drops in combination with Ranibizumab intravitreal injections in patients with diabetic macular edema. The study duration is 52 weeks and patients will be randomized to one of four treatment arms.

NCT ID: NCT02309476 Withdrawn - Clinical trials for Diabetic Macular Oedema

Sub-threshold Photocoagulation of Diabetic Macular Oedema

MEM
Start date: October 2012
Phase: N/A
Study type: Interventional

Topcon's Endpoint Management (EM) is a new software from the Pascal® laser which allows us to decrease the intensity of the burns (invisible burns) showing some landmarks with normal intensity so the investigators can see the area which has been treated. The Pascal® system with EM utilizes 577nm laser wavelength compared to the 532nm laser wavelength which was utilized in previous Pascal® laser studies. This study aims to demonstrate that 577nm Pascal® with EM has the same efficacy and effectiveness as 532nm Pascal® in the treatment of diabetic macular oedema.

NCT ID: NCT02281292 Withdrawn - Clinical trials for Diabetic Macular Edema

A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema

Start date: December 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the initial safety of intravitreal (IVT) LKA651 and potential for use alone or in combination with Ranibizumab ophthalmic solution (Lucentis®) for the treatment of Diabetic Macular Edema (DME) in patients with symptomatic disease.